We recently started a series called “Penny Stock of the Day”. These ideas are geared towards traders with an extremely high risk appetite.
Our Penny Stock of the Day is chosen by screening for stocks under $5 and then applying technical analysis on the shortlisted set of penny stocks showing unusual volume. When making these trades, please make sure to pay vigilant attention to pricing moves and have a strict stop loss in place to avoid significant losses.
Penny Stock of the Day: Autolus Therapeutics plc (NASDAQ: AUTL)
Today’s penny stock pick is the clinical-stage biopharmaceutical company, Autolus Therapeutics plc (NASDAQ: AUTL).
Autolus Therapeutics plc. develops T cell therapies for the treatment of cancer and autoimmune diseases in United Kingdom and internationally.
The company’s clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.
It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma.
Website: https://www.autolus.com/
Latest 10-K report: https://autolus.gcs-web.com/static-files/5ac982a5-a63f-48a1-8442-3c115c0cd021
Analyst Consensus: As per TipRanks Analytics, based on 5 Wall Street analysts offering 12-month price targets for AUTL in the last 3 months, the stock has an average price target of $7.93, which is nearly 324% upside from current levels.
Analysts | Source: TipRanks.com
Potential Catalysts / Reasons for the Hype:
- Hedge Funds Increased Holdings by 147.9K Shares Last Quarter.
Hedge Funds | Source: TipRanks.com
- AUCATZYL’s Q2 2025 net product revenue was reported to be $20.9 million and $29.9 for the first six months of 2025. Analysts noted it generated approximately $76M in its first year, with nearly 60 treatment centers activated ahead of schedule.
- Strong data from the CARLYSLE trial in severe refractory SLE (83% DORIS remission, 50% CRR in small cohort) and pediatric r/r B-ALL (95% ORR, durable remissions).
- Recent recommendations from NICE (UK) and progress with the EMA (EU) suggest a global revenue ramp-up is coming in 2025/2026.
- Speculation about a full acquisition by BioNTech. BioNTech already owns a ~12.5% stake and has a strategic partnership to use Autolus’ manufacturing.
On analyzing the company’s stock charts, there seem to be multiple bullish indications…
Bullish Indications
#1 Symmetrical Triangle Pattern Breakout: The daily chart shows that the stock has currently broken out a symmetrical triangle pattern, which is marked as purple color lines. A symmetrical triangle pattern represents a period of consolidation before the price breaks out. This is typically formed when there is indecision in the price movements and uncertainty among the buyers and sellers. Once a breakout from the upper trend line occurs, it usually signifies the start of a new bullish trend.
AUTL – Daily Chart
#2 Bullish ADX and DI: The ADX indicator shows bullishness as the +DI line is above the -DI line, and the ADX line is currently moving higher from below the +DI and -DI lines.
#3 Price above MAs: The stock is currently above its 50-day as well as 200-day SMA, indicating that the bulls have currently gained control.
#4 Bullish Aroon: The value of Aroon Up (orange line) is above 70 while Aroon Down (blue line) is below 30. This indicates bullishness.
#5 Above Support Area: The weekly chart shows that the stock is currently trading above a support area, which is marked as a pink color dotted line. This looks like a good area for the stock to move higher. The stock is also trading above its 50-week SMA, indicating that the bulls are gaining control.
AUTL – Weekly Chart
#6 Bullish Stoch: The %K line is above the %D line of the stochastic in the weekly chart, indicating possible bullishness.
#8 MACD above Signal Line: In the weekly chart, the MACD (light blue color) is currently above the MACD signal line (orange color). This indicates a possible bullish setup.
Recommended Trade (based on the charts)
Buy Levels: If you want to get in on this trade, the ideal buy level for AUTL is above the price of $1.90.
Target Prices: Our first target is $3.30. If it closes above that level, the second target price is $4.40.
Stop Loss: To limit risk, place a stop loss at $1.10. Note that the stop loss is on a closing basis.
Our target potential upside is 74% to 132%.
For a risk of $0.80, our first target reward is $1.40, and the second target reward is $2.50. This is a nearly 1:2 and 1:3 risk-reward trade.
In other words, this trade offers 2x to 3x more potential upside than downside.
Potential Risks / Red Flags:
- The company has a history of net losses.
AUTL – Consolidated Statements of Operations
- Cell therapy is notoriously expensive to scale. The CAR-T space is also quite crowded, with multiple players in oncology and autoimmune indications.
- Management noted a temporary sales lag in late 2025 due to changes in CMS (Medicare/Medicaid) reimbursement Any further bureaucratic hiccups in how CAR-T is paid for could hurt the stock.
- Despite being a loss-making company, the executives are being paid significant compensation.
AUTL – Executive Compensation
- The company’s product candidates are in clinical development or in preclinical development. If they are unable to advance the product candidates through clinical development, obtain regulatory approval and ultimately commercialize product candidates, or experience significant delays in doing so, their business will be materially harmed.
As you can see, today’s featured penny stock offers big upside potential… but it also comes with a number of risks and red flags. As always, when dealing with penny stocks, we advise caution before entering into such high-risk ventures. Remember to think before you trade… understand the risks… and if you decide to trade, stick to your stop-losses!
Happy Trading!
Trades of the Day Research Team
READ BEFORE TRADING PENNY STOCKS: The allure of penny stocks lies in their potential to deliver massive gains in a short period of time. However, in exchange for that opportunity, most penny stocks carry tremendous risk. They can be extremely volatile and are susceptible to “pump and dump” schemes and fraud.
Unlike regular stocks, the financial condition of most penny stock companies can be extremely difficult to analyze, as the majority of such stocks are traded on over-the-counter (OTC) exchanges, which are typically less transparent and less regulated than the major exchanges. In fact, in the penny stock space, it’s often easier to spot warning signs and red flags than it is to identify a sound investment. Nevertheless, we do our best to identify short-term trade opportunities in this exciting space because we know some of our readers are looking for high-risk, high-reward ideas. We just urge you to make sure you fully understand the risks before making any of these trades.
Did you spot this in the Oval Office last week? [sponsor]When Tim Cook stood in the Oval Office last week, all eyes were on the "unique 24K gold gift" he presented to President Trump. But many viewers missed an even more important moment in that 30-second clip. One that unmistakably singled out what Futurist Eric Fry calls "possibly the best AI investment anyone could make right now." Eric believes this little-known partner to Apple could go crazy over the next 12-24 months, potentially leaving well-known AI stocks like Nvidia, Microsoft and Google in the dust. Click to get full details on the company.